VanEck Junior Gold Miners vs Nuwellis Inc — how do they compare? VanEck Junior Gold Miners trades at $114.43 (market cap $8.22B), while Nuwellis Inc trades at $0.69 (market cap $2.20M). The key difference: VanEck Junior Gold Miners is far larger — about 3736.4× Nuwellis Inc's market cap, and VanEck Junior Gold Miners is trading nearer its 52-week high, Nuwellis Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold VanEck Junior Gold Miners for 41 Days and Nuwellis Inc for 26 Days on average.
| GDXJ | NUWE | |
|---|---|---|
Market Cap | $8.22B | $2.20M |
Volume | 3,212,198 | 121,544 |
Sector | Commodities - Metals/Agriculture | Health |
52-Week High | $156.19 | $146.65 |
52-Week Low | $87.56 | $0.68 |
Typical Hold Time | 41 Days | 26 Days |
Enterprise Value | — | -$1.52M |
Signals from Pluang's Aura AI — not financial advice
GDXJ, the VanEck Junior Gold Miners ETF, trades at $114.43, up 4.85% today, but technical indicators signal a bearish trend with moving averages and ADX pointing lower. The ETF is undergoing significant rebalancing, with multiple junior mining companies like Sinda Ltd. and Hemlo Mining Corp. being added to the fund as of September 2026, which may impact liquidity and composition. Key financial ratios are not applicable as this is an ETF tracking a basket of stocks.
The outlook is mixed; recent gold price strength above $4,400 (24/7 Wall Street, August 16, 2026) supports miner ETFs, but GDXJ's bearish technicals and institutional selling (Amundi reduced its stake by 50.5% as per Defense World, August 6, 2026) suggest caution. Risks include gold price volatility and the high-risk nature of junior miners. Investment appeal hinges on gold's momentum versus the ETF's technical weakness.
NUWE trades at $0.689, down 0.25% with a bearish technical signal despite oversold RSI readings. The company shows promising revenue growth (14% YoY in Q2 2026) and strong gross margins (69.69%), but faces significant profitability challenges with a -125.63% net income margin and negative cash flow. Recent news highlights console adoption growth and strategic expansions in pediatric care.
While NUWE's valuation metrics appear attractive (P/E 0.03, P/S 0.01), the company's persistent losses and negative cash flow present substantial risk. Analyst sentiment is mixed with a 50/50 buy/hold split. The stock offers speculative potential if management can achieve profitability, but requires careful risk assessment given current financial challenges.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
GDXJ provides exposure to small and mid-cap companies in the global gold and silver mining industry. It focuses on 'junior' miners involved in exploration and early production, featuring 2026 leaders like Pan American Silver and Coeur Mining.
Read more on GDXJ →Nuwellis, Inc. is a medical device company focused on developing and commercializing fluid management solutions. The company's primary product is an ultrafiltration system used in hospitals to remove excess fluid from patients with fluid overload, often associated with conditions such as heart and kidney failure. Nuwellis aims to improve patient outcomes and reduce healthcare costs through its specialized, innovative therapies.
Read more on NUWE →